Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TLR4 | O00206 | 14/20 | 0.42 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371591 | 1.00 | MAPK1 (0.42) | MAPK1TLR4LY96 | |
| SCHEMBL13296777 | 1.00 | MAPK1 (0.42) | MAPK1TLR4LY96 | |
| SCHEMBL12560694 | 0.91 | MAPK1 (0.49) | MAPK1TLR4LY96 | |
| SCHEMBL12560669 | 0.91 | MAPK1 (0.49) | MAPK1TLR4LY96 | |
| SCHEMBL12762965 | 0.91 | MAPK1 (0.49) | MAPK1TLR4LY96 | |
| SCHEMBL12763047 | 0.91 | MAPK1 (0.49) | MAPK1TLR4LY96 | |
| SCHEMBL12371590 | 0.88 | TLR4 (0.39) | MAPK1TLR4LY96 | |
| SCHEMBL13296761 | 0.88 | TLR4 (0.39) | MAPK1TLR4LY96 | |
| SCHEMBL12560681 | 0.86 | TLR4 (0.46) | MAPK1TLR4LY96 | |
| SCHEMBL12762967 | 0.86 | TLR4 (0.46) | MAPK1TLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152429-A1 | SODIUM SALT OF DISACCHARIDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND USE OF THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-7737129-B2 | Substituted liposaccharides useful in the treatment and prevention of endotoxemia | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20080227991-A1 | Sodium salt of disaccharide compound, production method and use of same | EISAI R&D MANAGEMENT CO., LTD. | 2008-09-18 | — | — | US | disclosed |
| US-20080214802-A1 | Substituted Liposaccharides Useful in the Treatment and Prevention of Endotoxemia | EISAI CO., LTD. (JP) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214802-A1 | Substituted Liposaccharides Useful in the Treatment and Prevention of Endotoxemia | LIPG, FUT6, UGCG | MAPK1 3870/4885TLR4 94/4885LY96 382/4885 |
| US-20080227991-A1 | Sodium salt of disaccharide compound, production method and use of same | MAN2A1, MAN2B2, MAN2B1 | MAPK1 460/4885TLR4 557/4885LY96 4701/4885 |
| US-20100152429-A1 | SODIUM SALT OF DISACCHARIDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND USE OF THE SAME | MAN2B2, MAN2A1, MAN2B1 | MAPK1 969/4885TLR4 1500/4885LY96 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.